ABBV vs BMY
By Alex · Tickerpine
AbbVie Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BMY |
|---|---|---|
| Price | $295.03 | $63.43 |
| Market cap | $521.50B | $129.66B |
| P/E ratio | 50.7 | 14.1 |
| ROE | — | 44.01% |
| Profit margin | 15.67% | 18.47% |
| Revenue growth | 10.30% | 6.90% |
| Dividend yield | 2.35% | 3.97% |
| Beta | 0.19 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BMY in plain English
- ABBV is the bigger company — about 4.0× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.1 vs 50.7).
- ABBV is growing revenue faster (10% vs 7%).
- BMY has the higher dividend yield (3.97% vs 2.35%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.